In addition to these US approvals, the PD-L1 SP263 assay was approved in Japan as a companion diagnostic for use with atezolizumab for NSCLC (36) and in Europe as a companion diagnostic for use with either atezolizumab or cemiplimab-rwlc in NSCLC (37, 38). This evidence concerns the gene CD274 and non-small cell lung carcinoma.